We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lectin-Based Test Estimates Glycated Hemoglobin

By LabMedica International staff writers
Posted on 29 Feb 2012
A novel method has been developed for estimating the glycated hemoglobin (HbA1c) in normal and diabetic patients using a glucose specific lectin. More...


The quantitative precipitin method was performed for the interaction between the glucose-specific lectin Concanavalin A (Con A) and the glucose-containing RBC-lysate for the estimation of calculated HbA1c% from a standard curve.

Scientists at the Cancer Centre Welfare Home and Research Institute, (Kolkata, West Bengal, India) selected 16 patients of both sexes with type-2 diabetes, age range 35–60 years, and four patients with newly diagnosed type-1 diabetes, age range 15–41 years . Twenty sex-matched normal healthy subjects, age range 33-65 years, were also included as controls. A precipitation test of red cell lysate and Con-A was performed and the precipitate estimated spectrophotometrically at 480 nm. For reference, plasma glucose was estimated from the diabetic and nondiabetic subjects by glucose oxidase method using phenol 4-aminophenazone and HbA1c% were measured by ion-exchange high performance liquid chromatography (HPLC) method with the Bio-Rad D-10 analyzer (BioRad; Hercules, CA, USA).

The absorbance range of the precipitate was 0.14–0.20 in normal subjects and the corresponding calculated HbA1c% along with plasma glucose levels was 4.1%-5.8% and 82-101 mg/dL, respectively. For the diabetic patients, HbA1c results were between 6.3%-12.2%, and the plasma glucose range was 120-292 mg/dL. Similar results were observed for HbA1c% (6.1%-11.9%) of the same diabetic samples measured by conventional ion-exchange HPLC. The nondiabetic and diabetic hemoglobin variant subjects consisted of HbE-β-thalassemia, β-thalassemia carrier state, HbE trait, and HbS trait, showed similar HbA1c% by the lectin-based assay when compared with standard HPLC method.

The authors concluded that the lectin-based assay may be adopted to estimate glycated hemoglobin level in differentiating between normal and diabetic patients. This assay offers a good correlation with standard HPLC method, and moreover, the method is convenient, cheap, and needs no sophisticated instruments, and therefore suitable for laboratories in poor resource settings. The study was published online on January 24, 2012, in the Journal of Clinical Laboratory Analysis.

Related Links:

Cancer Centre Welfare Home and Research Institute
BioRad




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.